A Real World Cohort Study Evaluating The Safety And Efficacy Of Ombitasvir/Paritaprevir/Ritonavir And Dasabuvir With Ribavirin (3D + R) For 12 Weeks In Patients With Hepatitis C Virus (HCV) Genotype lb Infection And Compensated Cirrhosis.
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2017 New trial record